Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

Sangretech’s technology will be used in the development and commercialization of VDC2008, Bostwick Scientific’s clinical stage product candidate employing unloaded or “virgin” dendritic cells in combination with cryotherapy (freezing) and other primary therapies to potentially treat prostate and other solid cancers. The first clinical trial in the United States employing this technology – the “CRITICAL” trial – will be led by Principal Investigators Drs. Duke Bahn and Mark Sholz at the Prostate Institute of America in Ventura, California and at Prostate Oncology Specialists in Marina del Rey, California.

Dr. Haakon Ragde, Sangretech’s founder, Chairman, and Chief Medical Officer, said, “We are very pleased to enter into this amended agreement with Bostwick Laboratories to enable trials using our technology. We have great faith that prostate and other cancer patients will benefit from this approach.”

Dr. David Bostwick, CEO and Medical Director of Bostwick Laboratories, commented, “Dendritic cell immunotherapy represents a promising new approach to cancer treatment. Bostwick Laboratories is committed to providing cancer patients with superior diagnostic and therapeutic services. We believe stimulating the immune system to fight disease could prove to be an important advance in the fight against cancer and are proud to sponsor the CRITICAL trial.”